Abstract
Compound LB20304 is a fluoronaphthyridone carboxylic acid with a novel pyrrolidine substituent. This drug was compared with ciprofloxacin, levofloxacin, ofloxacin, and trovafloxacin against over 800 pathogens, most from blood stream infections, by National Committee for Clinical Laboratory Standards reference methods. LB20304 was the most active agent against gram-positive species including strains observed to be resistant to other fluoroquinolones and glycopeptides. The potency of LB20304 (MIC50, 0.03 micrograms/ml) against the Enterobacteriaceae was exceeded only by that of ciprofloxacin (0.015 micrograms/ml). It has limited activity against gram-negative anaerobes.
Full Text
The Full Text of this article is available as a PDF (191.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Gootz T. D., Brighty K. E., Anderson M. R., Schmieder B. J., Haskell S. L., Sutcliffe J. A., Castaldi M. J., McGuirk P. R. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diagn Microbiol Infect Dis. 1994 Aug;19(4):235–243. doi: 10.1016/0732-8893(94)90037-x. [DOI] [PubMed] [Google Scholar]
- Jolley A., Andrews J. M., Brenwald N., Wise R. The in-vitro activity of a new highly active quinolone, DU-6859a. J Antimicrob Chemother. 1993 Nov;32(5):757–763. doi: 10.1093/jac/32.5.757. [DOI] [PubMed] [Google Scholar]
- Jones R. N., Kehrberg E. N., Erwin M. E., Anderson S. C. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group. Diagn Microbiol Infect Dis. 1994 Aug;19(4):203–215. doi: 10.1016/0732-8893(94)90033-7. [DOI] [PubMed] [Google Scholar]
- Klugman K. P. Pneumococcal resistance to antibiotics. Clin Microbiol Rev. 1990 Apr;3(2):171–196. doi: 10.1128/cmr.3.2.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Oh J. I., Paek K. S., Ahn M. J., Kim M. Y., Hong C. Y., Kim I. C., Kwak J. H. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob Agents Chemother. 1996 Jun;40(6):1564–1568. doi: 10.1128/aac.40.6.1564. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Swartz M. N. Hospital-acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2420–2427. doi: 10.1073/pnas.91.7.2420. [DOI] [PMC free article] [PubMed] [Google Scholar]